Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

Ross Camidge, MD, PhD, director, the Thoracic Oncology Clinical and Clinical Research Programs, the University of Colorado Anschutz Medical Campus, discusses toxicities observed with sunvozertinib (DZD9008) in EGFR Exon 20–Mutated non–small cell lung cancer (NSCLC).